Transcript Highlights:

• </c><04:12:00.640><c> hazardous</c> to exclude pharmaceutical hazardous to exclude pharmaceutical hazardous
• These are the DEA pharmaceutical takeback days that happen twice a year.
• drugs in there, no pharmaceutical drugs in there, no questions<04:13:42.560><c> asked.
• There's pharmaceuticals, there's heavy metals, there's other contaminants.
• </c><05:42:05.600><c> listed</c> are more than 6 million compounds listed are more than 6 million compounds

Keywords: 1189, house, all

Bills: SB8, SB4, SB43, SB1, SB2, SB13, SB6, SB10, SB16, SB14, SB3, SB8, SB4, SB43, SB1, SB2, SB13, SB6, SB10, SB16, SB14, SB3

Keywords: education, accountability, public school assessment, state law, transparency, intervention, performance ratings, Texas congressional redistricting, U.S. House districts, congressional map, redistricting, gerrymandering, 2020 Census, census tracts, block groups, voting districts, election law, Texas House of Representatives districts, federal congressional districts, 2026 elections

Transcript Highlights:

• But it doesn't prevent compounding; compounding can still occur if these checks are met. Mr.
• First, the FDA does not approve or disapprove compounded medications or active pharmaceutical ingredients
• Borg, how many GLP-1 doses are you compounding? How many GLP-1 are we compounding?
• We do compound some GLP-1.
• used in compounding.

Summary: The committee began with a presentation from Berthold Barak Karlich of Benor Capital on investment and innovation from a European perspective. He argued that legacy in trade and innovation is about enabling future generations, not isolation, and highlighted Austria and Europe’s strengths in education, applied research, hidden-champion SMEs, and deep-tech. He also warned against economic nationalism and emphasized that entrepreneurship and cross-border trade create shared interests, peace, and long-term collaboration. In response to questions, he said Arizona had impressed him as a strong, international deep-tech hub, and he expressed interest in learning more about opportunities there. The committee then considered HB 2746, which creates a study committee on trade offices under the Arizona Commerce Authority to review existing trade offices, gather stakeholder input, and report recommendations by December 31, 2028. Members discussed oversight of Arizona’s trade offices in countries including Mexico, Korea, Taiwan, Japan, Romania, and Germany, and the sponsor said the bill would help evaluate effectiveness while identifying new opportunities. The bill received a due pass recommendation on a 7-0 vote. HB 2750, which establishes the Arizona-Sonora Trade Commission with legislative appointees, also received a due pass recommendation after members discussed its role as a complement to executive-branch efforts; it passed 5-1 with one present. The committee next heard HB 4036, a bill restricting the sale and distribution of compounded GLP-1 weight-loss drugs made with certain bulk drug substances and authorizing inspections by the State Board of Pharmacy. Supporters, including Novo Nordisk and the Partnership for Safe Medicines, argued the bill would address unsafe imported ingredients, impurities, misleading advertising, and a surge in mass compounding that they said exceeds the intent of compounding law. Opponents from the Arizona Pharmacy Association, compounding pharmacists, and a physician argued the bill would burden lawful compounders, raise costs, reduce access, and could harm patients who rely on compounded medications. After extensive debate, the committee failed to pass HB 4036 on a 5-5 vote. Finally, the committee took up HB 2765, as amended by a strike-everything amendment creating a vapor product manufacturer licensing framework, fees, penalties, and Department of Revenue oversight. The sponsor said the measure was intended to address illegal smuggling of vape products and protect children, while opponents argued it would burden lawful businesses and that the real problem was illicit actors outside the regulated market. The transcript ends during the discussion of this bill, before a final vote is recorded.

Transcript Highlights:

• What is important to understand is that these two compounds, mitragynine and 7-OH, are not really equal
• Second, one kratom-related compound, specifically 7-OH, behaves much more like a traditional opioid than
• now is the spread and uncontrolled spread of products that concentrate Spread and concentrate this compound
• That kind of drug development is the purview of pharmaceutical companies and FDA approval.
• It doesn't cure it, but it helps me control it and helps me maintain it without going pharmaceutical,

Summary: The committee held an informational hearing on kratom and 7-hydroxymitragynine (7-OH), focusing on public health risks, overdose deaths, and regulatory gaps in California. The chair opened by noting that FDA and CDPH consider kratom and 7-OH products unlawful for consumption, yet they remain widely sold in smoke shops, vape stores, gas stations, and convenience stores. The hearing was framed as part of ongoing legislative work, including a future review of AB 1088, and members emphasized the need to weigh potential benefits against risks and consider whether stronger safeguards are needed. Expert testimony from a toxicology professor and several public health and medical officials described kratom as a plant with multiple alkaloids, with 7-OH identified as the more potent opioid-like compound associated with tolerance, dependence, withdrawal, and respiratory depression. CDPH reported 362 kratom-related overdose deaths in California from 2019 to 2023 and 15 deaths involving 7-OH, while Los Angeles County officials described unexplained deaths in young adults that led them to expand toxicology testing and identify 7-OH as a common factor. County and state public health representatives said they have issued advisories, contacted retailers, removed products from shelves, and taken enforcement actions, but they stressed that local enforcement is patchy, under-resourced, and limited by unclear jurisdiction and lack of testing capacity. Medical witnesses said patients are presenting with 7-OH dependence and withdrawal in ways similar to fentanyl-related cases, sometimes requiring buprenorphine, methadone, or repeated naloxone. They argued that unregulated retail sales and misleading marketing make the products especially risky, and that a statewide framework would be more effective than a patchwork of local ordinances. Some officials said the safest current policy is to keep kratom and 7-OH unlawful for consumption, while others said any new regulation would need resources, packaging rules, and clearer authority for enforcement. Industry and consumer advocates urged the committee to distinguish natural kratom leaf from concentrated or synthetic 7-OH products. They argued that kratom leaf has long-standing use, that 7-OH should be targeted rather than the whole plant, and that regulation should focus on age limits, labeling, testing, serving-size caps, and restrictions on adulterated products rather than prohibition. Several speakers warned that bans could push demand to the black market and reduce access for people using the products for pain relief or harm reduction, while critics of the industry said the products are being marketed deceptively and that more comprehensive regulation is needed.

Transcript Highlights:

• Natural leaf contains lower, more balanced levels of compounds.
• In 2025, the FDA recommended focusing only on 7-OH, the high-potency synthetic and adulterated compound
• Kratom, like a... ...including alcohol, opioids such as fentanyl, and other pharmaceuticals.
• Kratom, like every pharmaceutical or supplement you take, may have side effects in some persons.
• I've gone through dozens of pharmaceuticals and I ended up on opioids just a small amount, not enough

Summary: The committee first recognized a departing page, Jonathan, thanked him for his service, and approved the March 2, 2026 minutes. Members then reviewed committee procedure and took up Senate Bill 1419, the Idaho Child Care Program. Representative Jordan Redman presented the bill as a policy measure to tighten eligibility, require work or training, lower the asset cap, add anti-fraud measures, require provider registration, and sunset the program in 2028. Department of Health and Welfare Director Juliet Sharon said the department already had authority to audit and take administrative action, but the bill would add stronger tools, including clearer provider requirements and concurrent jurisdiction for the Attorney General to pursue criminal fraud cases. She also clarified the program’s federal funding structure and said the department could potentially address the foster-care eligibility concern through temporary rules. Testimony was split: Idaho Voices for Children, foster-care advocates, and several providers argued the bill was not a clean transfer from rule to statute, could create gaps in eligibility and new audit costs, and might reduce access for foster families and low-income parents; supporters, including the Foundation for Government Accountability and some legislators, emphasized program integrity, fraud prevention, and legislative oversight. After debate over whether the bill should be held or advanced, the committee voted 6-4 to send SB 1419 to the floor with a do-pass recommendation. The committee then began Senate Bill 1418, a kratom regulation bill, and the sponsor, Senator Tammy Nichols, said she would request it be sent to the 14th order for amendments, including clarifications for Idaho State Police and additional labeling changes requested by the Idaho Association of Physicians. Nichols described the bill as a regulatory framework that distinguishes natural kratom leaf from adulterated or synthetic products, sets age limits, testing and labeling requirements, and enforcement tools aimed at high-potency 7-hydroxymitragynine products. Testimony was sharply divided. Supporters, including a toxicologist, a consumer, and an addiction medicine specialist, argued that kratom should be regulated rather than banned, that the bill targets dangerous adulterated products, and that a full ban could drive use underground or toward more dangerous opioids. Opponents, including an ER physician, a bereaved parent, and the Idaho Chiefs of Police, argued kratom is addictive and harmful, that the bill does not go far enough to protect the public, and that enforcement would impose significant costs on Idaho State Police without meaningful authority. Committee members raised concerns about fiscal impacts, local control, and whether the bill effectively bans or regulates the product, and the sponsor and witnesses continued responding as testimony proceeded.

Transcript Highlights:

• Um, it'll shift powers to the pharmaceutical industry where cannabis has never caused a single death.
• That can't be said for pharmaceutical drugs. Um, okay. I'd love to answer any questions.
• And I can tell you, I do not know those compounds either.
• And I can admit I'm ignorant when it comes to all of the chemical compounds.

Bills: HB1

Keywords: DUI, driving under the influence, ignition interlock, interlock device, driver license suspension, restricted license, motor vehicle, alcohol offense, first offense, repeat offender, blood alcohol concentration, BAC, license revocation, Alabama State Law Enforcement Agency, ALEA, public safety, traffic safety, chemical dependency, substance abuse, court referral program

Transcript Highlights:

• As prime contractors are liable for subcontractor compliance, this risk compounds.
• As prime contractors are liable for subcontractor compliance, this risk compounds.
• happy to be here to present SB 1185, which applies skilled and trained workforce standards to pharmaceutical
• Pharmaceutical facilities are among the most technically complex construction environments in the modern
• all future construction, alteration, repair, installation, demolition, and maintenance work at pharmaceutical

Keywords: 988, house, all

Transcript Highlights:

• </c><00:07:54.120><c> from</c><00:07:54.440><c> large</c> buy Pharmaceuticals from large buy Pharmaceuticals
• </c> for-profit uh pharmaceutical companies for-profit uh pharmaceutical companies you<00:07:58.120><
• Pharmaceuticals and drugs are up 12 to 15% year over year, including supply costs going up in the 10%
• Pharmaceuticals and drugs are up 12 to 15% year over year, including supply costs going up in the 10%
• Inflation, as has been mentioned, with pharmaceuticals, high-tech, and equipment.

Keywords: 1183, house

Transcript Highlights:

• Most compounders just test for the active ingredient.
• Compounding is, by definition, individualized.
• And one of the points I want to make to everyone is while compounding, we believe in compounding, but
• It doesn't compound anyway.
• It doesn't compound anyway.

Keywords: 988, house, all

Transcript Highlights:

• But these products are manufactured by pharmaceutical companies, mostly.
• Do any of you have a prescription for a pharmaceutical of some kind? Is it really safe?
• But if you actually look at the chemical compounds, it is tetrachlorodibenzio per-dioxyxide.
• But if you actually look at the chemical compounds, it is tetrachloridibenzio pero-dioxyxide.
• These compounds that we're dealing with and utilizing in agriculture are of that vintage.

Keywords: 908, all

Summary: The House convened with prayer, roll call, and a quorum present, then took up several procedural motions, including suspending House rules for three legislative days and replacing conference committee members on Senate Bill 2282 and SCR 4007. The chamber also recognized visiting student groups from Grafton/Pleasant Valley and Shiloh School. Later, the House agreed to several conference committee reports and moved a number of measures through final passage or final disposition. House Bill 1428, which would have created a sales tax exemption for clothing sold by thrift stores or nonprofit corporations, drew extensive debate over tax policy, revenue loss, and possible conflicts with streamlined sales tax rules. Supporters argued it would help lower-income shoppers and nonprofit thrift stores, while opponents said it created an unfair advantage and could reduce state and local revenue. The conference report was adopted, but the bill ultimately failed on final vote, 37-54. House Bill 1440, relating to cigar lounges, was amended in conference and then passed 75-17. House Bill 1460, concerning adult foster care for private-pay adults, electronic monitoring, and a legislative study, was also adopted and passed overwhelmingly, 91-1. The House then passed Senate Bill 2224, which revises gaming commission structure and gaming stamp requirements, adds Attorney General enforcement provisions, and includes a $25,000 general fund appropriation, by a vote of 88-0. Senate Bill 2327, which expands uses of the agriculture diversification and development fund and appropriates $15 million to it, passed 74-17 after a member was excused from voting due to a personal interest. Senate Bill 2267, creating a regulatory framework for on-site wastewater treatment systems and shifting licensing authority to the Department of Environmental Quality, passed 82-10, and Senate Bill 2276, addressing joint water resource boards for cross-county projects, passed 90-1. The most contentious debate centered on Senate Bill 2160, which would move the state employee health plan from grandfathered status to a non-grandfathered ACA-compliant plan and appropriate about $6.6 million for the transition. Supporters said it would give the PERS board more flexibility, expand preventive and other benefits, and potentially slow premium growth without charging employees premiums. Opponents warned it could raise out-of-pocket costs, add mandated benefits, and shift costs to employees, while also arguing the bill had not been adequately studied. After extended debate, the House passed SB 2160 by a vote of 55-37. The chamber also concurred in Senate amendments to House Bill 1318, a pesticide labeling bill, and placed it on final passage, but the transcript ends before the final vote on that measure.

Transcript Highlights:

• What is important to understand is that these two compounds, mitragynine and 7-OH, are not really equal
• Second, one kratom-related compound, specifically 7-OH, behaves much more like traditional opioids than
• largest concern right now is the spread and uncontrolled spread of products that concentrate this compound
• So while we're discussing this compound today, we all In the future.
• That kind of drug development is the purview of pharmaceutical companies and FDA approval.

Keywords: 987, senate, all

Transcript Highlights:

• The scale of GLP-1 compounding is unprecedented.
• The scale of GLP-1 compounding is unprecedented.
• I'm a compounding pharmacist, a board-certified sterile compounding pharmacist.
• Compounded drugs are not FDA-approved.
• This bill doesn't suggest compounded drugs should be FDA-approved, and it doesn't suggest that compounded

Summary: The committee heard several bills, beginning with AB 1921 on video game shutdowns. The author and Consumer Reports supported requiring game operators to give 60 days’ notice before ending server support and to offer a menu of remedies, including refunds or playable/offline alternatives, while the Entertainment Software Association opposed the bill as an unwarranted new standard for digital products and raised safety and legal concerns about community servers. Members questioned the scope of refunds, copyright, and community-server issues, and the author said he was open to further amendments. The bill was moved on a due-pass motion to Senate Appropriations and placed on call. AB 1965, dealing with cannabis testing, was presented as a measure to strengthen the Department of Cannabis Control’s authority over testing labs and improve product safety and transparency. The California Cannabis Operators Association supported the bill, saying it would help ensure consistent standards and protect consumers in a market with a large illicit component. There was no opposition, and the bill was moved on a due-pass motion to Senate Appropriations and placed on call. The committee also heard AB 2141, which would allow the Board of Pharmacy to resolve certain disciplinary matters through a voluntary pre-accusation settlement process. The author and a supporting pharmacist said it would speed resolution of smaller, technical cases and reduce costs, while a member raised concerns about transparency and whether the public would have less information about licensee misconduct. The bill passed the committee on a due-pass motion to Senate Appropriations, with Senator Menjivar voting no, and was placed on call. AB 2163, creating strategic clean energy and critical mineral development zones, was supported by the author and Imperial County as a way to prioritize geothermal and lithium development in areas like the Salton Sea region; it passed on a due-pass motion to Senate Appropriations and was placed on call. Later, AB 1990 on compounded weight-loss drug advertising drew significant debate. Supporters argued it would curb misleading ads and require disclosures about risks and non-FDA approval, while opponents from the compounding pharmacy community said it would create burdens, duplicate existing false-advertising law, and could harm patient access. Members questioned whether the bill actually addressed targeting minors and whether it would force use of FDA-approved labeling; the author said the bill was meant to add specificity and guardrails. The bill was moved on a due-pass motion to Senate Judiciary, with some no votes, and placed on call. The committee also heard AB 2783 on court reporters, which would add a national certification pathway and extend a remote reporting pilot; it drew support from court reporting stakeholders and passed unanimously on a due-pass motion to Senate Appropriations, placed on call. Finally, AB 2771, the Bureau for Private Postsecondary Education sunset bill, and AB 2772, the interior design certification sunset bill, were presented and heard with mixed testimony: AB 2771 received support from student and borrower advocates and was moved to Senate Education, while AB 2772 drew both support and strong opposition over CCIDC governance and accountability, with the committee hearing extensive public comment before the transcript ended.

Transcript Highlights:

• TAKE ADVANTAGE OF COMPOUND INTEREST. PLAN AHEAD.
• and pharmaceutical ingredients on the national security of the United States.
• In Proclamation 11020 of April 2nd, 2026, adjusting imports of pharmaceuticals and pharmaceutical ingredients
• I concur with the Secretary's findings that pharmaceuticals and associated pharmaceutical ingredients
• and pharmaceutical ingredients.

Keywords: U.S. House of Representatives Floor Proceedings on Monday, April 20, 2026, 1012, house, all

Transcript Highlights:

• chemistry, toxicology, and health risk of botanical products, including kratom and kratom-derived compounds
• What is important to understand is that these two compounds, mitragynine and 7-OH, are not really equal
• Second, one kratom-related compound, specifically 7-OH, behaves much more like traditional opioids than
• That kind of drug development is the purview of pharmaceutical companies and FDA approval.
• It doesn't cure it, but it helps me control it and helps me maintain it without going pharmaceutical,

Summary: The committee held an informational hearing on kratom and 7-hydroxymitragynine (7-OH), focusing on public health risks, overdose deaths, and regulatory gaps in California. The chair opened by noting that FDA and CDPH consider kratom and 7-OH products unlawful, yet they remain widely sold in smoke shops, vape stores, gas stations, and convenience stores. Members referenced AB 1088, which would be considered later, and said the hearing was intended to clarify the science, medical perspective, and whether stronger safeguards are needed. The first panel featured a toxicology expert, state and local public health officials, an emergency/addiction physician, a medical examiner, and county health representatives. Witnesses from CDPH and Los Angeles County described rising deaths and enforcement actions, including statewide advisories, retailer letters, and product removals from manufacturers, wholesalers, and retailers. Medical testimony emphasized that 7-OH acts much more like an opioid than traditional kratom leaf, can cause dependence, withdrawal, and respiratory depression, and may require naloxone, buprenorphine, or methadone in overdose or withdrawal cases. Local officials said enforcement is difficult because packaging is inconsistent, testing capacity is limited, and counties lack resources and statewide infrastructure; they generally favored a centralized state framework if regulation is pursued. Committee members asked about testing, age restrictions, scheduling, and whether a distinction between kratom and 7-OH could be enforced. Witnesses said forensic labs can potentially test for 7-OH but validated assays are not routine, emergency departments cannot readily distinguish exposures, and local health departments do not have the lab capacity to verify product labels. Several officials warned that a ban or abrupt scheduling could push products into the black market and discourage research, while others argued that current prohibition and enforcement are the most protective approach because legalization or age-limited regulation could create confusion about legality and safety. The second panel included kratom and 7-OH advocates and industry representatives, who argued that natural kratom leaf and concentrated or synthetic 7-OH are different products and should be regulated differently. They supported age-gating, labeling, testing, and packaging rules for kratom leaf while opposing a ban on the botanical. They said 7-OH is used by many adults for pain relief or harm reduction, and that prohibition would drive consumers to illicit markets and worsen harm. Committee members pressed them on whether 7-OH is more potent than kratom, the availability of testing, and whether any safe dose is known. The hearing ended without a vote or formal action, with the chair noting the issue will continue to be considered in future legislation.

Bills: HB 1106, HB 3284, HB 541, HB 713, HB 1403, HB 1586, HB 1942, HB 2070, HB 2844, HB 2851, HB 3151, HB 3749, HB 3940, HB 3963, HB 4454, HB 4466, HB 4795, HB 5154, HB 5394, SB 1357, HB 1052, HB 4099, HB 4638, HB 5147

Keywords: child abuse, neglect, gender identity, sexual orientation, child welfare, marriage, family, Texas Commission, family welfare, marriage support, stability, premarital education, child development, strong families, direct patient care, healthcare, physicians, medical services, insurance regulation, maternal health

Bills: HB 1106, HB 3284, HB 541, HB 713, HB 1403, HB 1586, HB 1942, HB 2070, HB 2844, HB 2851, HB 3151, HB 3749, HB 3940, HB 3963, HB 4454, HB 4466, HB 4795, HB 5154, HB 5394, SB 1357, HB 1052, HB 4099, HB 4638, HB 5147

Keywords: child abuse, neglect, gender identity, sexual orientation, child welfare, marriage, family, Texas Commission, family welfare, marriage support, stability, premarital education, child development, strong families, direct patient care, healthcare, physicians, medical services, insurance regulation, maternal health

Transcript Highlights:

• But my next part of that would be what pharmaceutical coverage is...

Bills: HB1464, HB1635, HB2516, HB3317, HB3502, HB4012, HB4268, HB4386, HB4877, SB916

Keywords: prescription drugs, drug pricing, pharmacy benefits, health insurance, health benefit plan, insurer, HMO, self-insured employer, public employer, school district, county, municipality, university system, higher education, retirees, dependent coverage, stop-loss coverage, bulk purchasing, group purchasing, purchasing pool

Transcript Highlights:

• It's what the pharmaceutical industry negotiates their prices on.
• I represent the Pharmaceutical Care Management Association, the nation's trade association for the PBM
• We asked pharmaceutical manufacturers.
• These are not compounded drugs. These are not, like, those sorts of things.
• These are not compounded drugs. These are not, like, those sorts of things.

Summary: The Senate Committee on Insurance met on May 6, 2026, and first reported HB 1241 favorably. That bill, by Chairman Furman, requires insurers to check with DCFS before paying certain insurance settlements to determine whether the recipient owes delinquent child support, and to withhold and remit arrears if found. DCFS explained that Louisiana already has intercepts and other collection tools, but no current mechanism for insurance settlements. Senators raised concerns about notice to obligors and about liability if insurers fail to withhold, but the bill was advanced without objection. The committee then heard HB 870, which would require health insurers and PBMs to cover lower-cost generic or biosimilar drugs when available and to use utilization management no more restrictively on those drugs. Supporters said the bill would improve access and lower patient costs by using wholesale acquisition cost as the comparison point. Opponents, including Louisiana Blue and the AFL-CIO, argued that WAC ignores rebates and net cost, could force plans to cover higher-cost biosimilars first, and could increase premiums and disrupt ERISA and fully insured plan design. The committee adopted a technical amendment set and then a second amendment set that added notice and reporting requirements tied to net cost calculations, and HB 870 was reported favorably as amended. Several other bills were moved with little or no opposition. HB 1176, concerning Medicare Advantage coverage for integrative cancer treatments such as cold cap therapy, cryotherapy, and acupuncture, was amended to change the effective date and then reported favorably. HB 1196, dealing with colorectal cancer screening follow-up colonoscopies, was also amended and reported favorably. HB 1162, a consumer protection bill requiring DOI to verify that a contractor named on a first-party property damage check is licensed in Louisiana, was amended and reported favorably. HB 826, which modernizes insurance referral rules to allow referrals by email or website address, was reported favorably. The committee also heard HB 1151 on insurer investment limits and solvency protections, and HB 1236 on pharmacy reimbursement and copay maximizer programs; both drew substantial testimony and concern, especially over retroactivity, PBM cost allocation, and whether copay maximizers shift costs to patients, but the transcript cuts off before final action on HB 1236.

Transcript Highlights:

• causes, prevention, treatment, and rehabilitation of dementia, the development of therapies and pharmaceuticals
• I am firmly convinced that we will not find a solution for cancer until the pharmaceutical companies
• And you're right; it's very compounded by the baby boomer generation because all of this activity is.
• This approach, very different from pharmaceuticals and sometimes known as electroceuticals, has had a
• I have just currently left my job at the ... ...after 20 plus years in pharmaceutical and medical sales

Bills: SB5, SJR3, SB 5, SJR 3

Keywords: dementia, research institute, Alzheimer's disease, Parkinson's disease, funding, grants, state health initiatives, research funding, state budget, prevention, healthcare, medical research, Dementia Prevention and Research Institute, disaster relief, flood preparedness, emergency funding, local government support, meteorological forecasting, district apportionment, legislative rules

Transcript Highlights:

• Medical, surgical, dental, chiropractic, hospital, optometric, potiatric, pharmaceutical, ambulance,
• It protects older adults from compounding financial harm, supports economic security, and their ability
• Importantly, that judgment has been compounding interest at Washington's judgment interest rate of 9%
• And finally, respectfully, the interest has been identified several times this morning as a compounded
• Simple interest does not grow exponentially the way compounded interest does.

Bills: SB5720, SB5833, SB5936, SB5993, SB5735

Keywords: consumer debt, judgment, uniformity, legal standards, debt collection, pets, motor vehicles, animal welfare, public safety, legislation, human trafficking, prevention, remedies, victims, law enforcement, support services, medical debt, interest charges, consumer protection, healthcare